As many of you who follow Disability Depot already know, my wife suffers from ME/CFS. In relation to this debilitating disease, she suffers from Orthostatic Intolerance, as well. Orthostatic Intolerence, or OI, is the inability to remain upright without suffering a number of symptoms which range in severity from nausea to passing out. As a partner of an OI sufferer, believe me, it’s almost as scary to see in person, as I imagine it is for the person experiencing it. I can’t tell you how many times I’ve seen Capricious stand up, only to fall right back down, or take a few steps and begin to crumple to the floor. It’s horrifying, to say the least. OI is common to those who suffer from ME/CFS, and many doctors recommend support stockings, as well as rehydrating drinks such as powerade or gatorade to help fight the condition, and frankly they do a piss-poor job. However, a recently financed study may result in a plan to alleviate OI in people with ME/CFS.
Recently, The NIH announced that it has awarded a $246,000 grant to Professor Marvin Medow of New York Medical College for the study of reducing OI in patients with ME/CFS through the use of oral rehydration. The purpose of the study is to find out if isotonic oral rehydration solution (ORS), might be a good candidate to help those who suffer from chronic OI. ORS, which has been used to re-hydrate cholera victims by the World Health Organization since 1978, is a mixture of both glucose and potassium, which are vital to maintaining the bodies blood volume and heart health. The solution is widely available through sites such as Amazon, and from comments and feedback left on the site, it’s easy to tell it is already largely used by those who suffer from chronic dehydration, though common sense tells me it could be dangerous to use ORS without medical supervision.
There are a number of concerns with over hydrating the body. Also, potassium is vital to heart health and at too low or high a dosage can be fatal and regular glucose intake at too high of levels can cause issues with diabetes or other problems with your pancreas. The study can provide clarity on whether or not ORS is effective, but should also provide guidelines on how to administer ORS in safe amounts and what, if any, are the effects of taking ORS long term. I am hopeful that this one will bear fruit ripe enough to bring satisfaction to those who chronically suffer from Orthostatic Intolerance. I wish you the best of luck Professor Medow, we all look forward to your findings.